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Abstract 
Upon activation platelets how elevated protein tyrosine phosphorylation, and translocation of the protein tyrosine kinase pp60 csrc 
from the plasma membrane to the cytoskeleton occurs. We therefore investigated whether tyrosine phosphorylation also increases in the 
cytoskeletal compartment. Here we show that almost identical patterns of phosphotyrosine-containing proteins are detectable in the 
cytoskeleton after platelet stimulation with compounds that directly (phorbol 12-myristate, 13-acetate) or indirectly (thrombin, vaso- 
pressin, collagen, ADP) activate protein kinase C. The apparent molecular masses of the proteins phosphorylated at tyrosine residues are 
145, 130, 100, 85, 80, 60, 56, 54 and 38 kDa. Elevation of cyclic AMP by prostaglandin E 1 had no effect. Concentrations of thrombin as 
low as 0.01 units per ml are able to cause tyrosine phosphorylation of multiple proteins. The time course of protein tyrosine 
phosphorylation for thrombin- and vasopressin-stimulated platelets revealed a rapid increase in the cytoskeleton within 5 to 20 s following 
activation consistent with a role in early events of platelet function. 
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1. Introduction 
A prominent event accompanying platelet activation is 
the increase in tyrosine phosphorylation of multiple pro- 
teins (for a review see Ref. [1]). Since all known platelet 
agonist receptors lack intrinsic protein tyrosine kinase 
activity, tyrosine phosphorylation is thought to be due to 
nonreceptor protein tyrosine kinases (PTKs), which are 
abundant in platelets (for reviews see Refs. [2] and [3]). 
The PTK pp60 c-src and, in smaller amounts, five other 
members of the src-family have been identified in human 
platelets [4-8]. Although sew~ral laboratories have reported 
that no enzymatic activation of pp60 c-src occurred upon 
thrombin stimulation [6,7,9,10], recent data demonstrate 
that pp60 csrc becomes activated [11-13]. Additionally, 
p125 FAK [14] and pp72 ~yk [1.5] might contribute to protein 
tyrosine phosphorylation i platelets. 
Abbreviations: ACD, acid-citrate-dextrose; ADP, adenosine diphos- 
phate; Gp IIb-IIIa, glycoprotein complex lib-Ilia; PGE1, prostaglandin 
Eft PKA, cyclic AMP-dependent protein kinase; PKC, calcium, phospho- 
lipid-dependent protein kinase; PMA, phorbol 12-myristate, 13-acetate; 
PRP, platelet-rich plasma; PTK, protein tyrosine kinase (EC 2.7.1.112) 
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Recently, it has also been shown that in activated 
platelets pp60 ..... translocates to the cytoskeleton [16-19], 
probably bringing the kinase in close proximity to poten- 
tial substrates. Since protein tyrosine kinase translocation 
seems to be a consequence of platelet activation and 
aggregation [17-20], we investigated the rise in phospho- 
tyrosine content in the cytoskeleton of stimulated platelets. 
Here, we demonstrate that a rapid induction of tyrosine 
phosphorylation of a number of proteins found in the 
cytoskeletal fraction occurs following platelet activation by 
various agonists. 
2. Materials and methods 
2.1. Platelet preparation 
Human platelets were prepared essentially as previously 
described [21]. Briefly, blood was taken from healthy 
volunteers who had not used acetylsalicylic acid for the 
previous 2 weeks. Blood samples were collected into ACD 
(Biotest, Dreieich, Germany) which was used as an anti- 
coagulant (6 vols. of venous blood to 1 vol. of ACD). 
Platelet-rich plasma (PRP) was prepared by centrifugation 
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of anticoagulated blood for 20 min at 120 X g at room 
temperature. The PRP was mixed with 111 /zl ACD per 
ml of PRP and 2-5 units apyrase per ml (grade III, Sigma, 
Miinchen, Germany). The platelets were isolated by cen- 
trifugation for 7 min at 650 X g, washed twice with a 
buffer containing 137 mM NaC1, 2.7 mM KCI, 12 mM 
NaHCO 3, 0.42 mM NaH2PO4, 5.6 mM glucose, 2 U/ml  
hirudin (Pentapharm, Frankfurt, Germany) and apyrase 
(2-5 U/ml) at a pH of 6.4 to prevent aggregation. Platelets 
were incubated at 37°C for 10-15 min before each centrif- 
ugation step. Finally, the platelets were resuspended in a 
suspension buffer similar to the washing buffer but without 
aggregation blocking compounds and including 2 mM 
CaC12 and 2 mM MgCI 2 at a pH of 7.4. The platelet 
suspension was adjusted to 3-5-  108 cells/ml, and incu- 
bated at 37°C for 45-75 min before incubation with 
biologically active agents. 
2.2. Platelet stimulation and preparation of  the cytoskele- 
ton 
Washed platelets were stimulated by addition of 15 /xl 
of the biologically active agent to 135 /zl of platelet 
suspension for a total volume of 150 /~1 in a 10-ml 
polystyrene centrifuge tube. During stimulation, the sus- 
pension was extensively stirred by two stainless steel 
spheres (diameter 2 mm) at 37°C. Incubation was stopped 
by addition of an equal volume of ice-cold isotonic lysis 
buffer as described previously by Fox et al. [22] containing 
2% (v/v)  Triton X-100, 100 mM Tris-HCl (pH 7.4), 10 
mM EGTA, 50 mM benzamidine, 2 mM phenylmethyl- 
sulfonyl fluoride, and 0.2 mM leupeptin, modified by 
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Fig. 1. Phosphotyrosine proteins in the Triton-insoluble cytoskeleton 
fraction of platelets stimulated byvarious agonists. I olated platelets were 
incubated for 60 s with various agonists. Triton-insoluble fractions were 
isolated as described in Section 2and immunoblotted with an anti-phos- 
photyrosine monoclonal antibody. Lanes: 1, control; 2, dimethylsulfoxide 
(DMSO), 0.01% (v/v); 3, thrombin, 1 U/ml; 4, collagen, 0.01 mg/ml; 
5, PMA, 0.01 /xg/ml in 0.01% DMSO; 6, ADP, 20 p.M; 7, PG Ea, 2.5 
/.~M. Each lane represents the Triton-insoluble material from 6.8.10 6 
platelets. The apparent molecular masses of the marker proteins inkDa 
are indicated atthe left. 
addition of 0.1 mM sodium orthovanadate and 0.02 mM 
ZnC12. The samples were mixed immediately and kept on 
ice for 20 min. The cytoskeleton of the lysed platelets was 
prepared by centrifugation for 4 min at 15 600 X g at 4°C 
[22]. The supernatant from this centrifugation step was 
used as the Triton-soluble fraction. The cytoskeleton- 
containing pellets were rinsed in 50 /zl of half-con- 
centrated lysis buffer, recentrifuged (15 600 X g, 4 min), 
and resuspended with 120 /zl of a 95°C solution of 2% 
(w/v)  SDS, 0.1 mM sodium orthovanadate, and 0.02 mM 
ZnC12. Aliquots were taken for a protein assay as de- 
scribed [23], except that only one third of the stated 
volumes was used, and diluted samples of 200/zl in 0.1% 
(w/v)  SDS were assayed. Samples were heated at 95°C in 
sample buffer (10% (w/v)  SDS, 10% (v/v)  /3-mercapto- 
ethanol, 20% (v/v)  glycerol, 6 M urea, 125 mM Tris-HC1 
(pH 6.8), traces of bromphenol blue) for 5 min and stored 
at 70°C until use. Thrombin, [ArgS]vasopressin, sodium 
nitroprusside, prostaglandin El, phorbol 12-myristate, 13- 
acetate (PMA) and leupeptin were purchased from Sigma 
(Miinchen, Germany). Collagen was from Nycomed 
(Miinchen). ADP was obtained from Boehringer Mannheim 
(Mannheim, Germany). 
2.3. Western blotting 
Proteins were resolved on 11% SDS/polyacryamide 
gels and transferred to nitrocellulose (Schleicher und 
Schuell, Dassel, Germany) within 4 h at constant 250 mA 
current in a wet-transfer chamber (BioRad, Miinchen). 
Blocking and incubation with antibodies were essentially 
performed as described elsewhere [24], except that the 
bovine serum albumin was not the fatty acid-free quality; 
also, incubation with the second antibody (125I-labelled 
sheep anti-mouse antibody; 750-3000/zCi per/xg; Amer- 
sham, Braunschweig, Germany; used at 1 /xCi/ml in the 
incubation mix) was for 2 h, and the washing steps were 
tripled to give a low background. Anti-phosphotyrosine 
monoclonal antibody was obtained from Sigma (Miinchen) 
and anti-pp60 src antibody (mAb 327) was obtained from 
Dianova (Hamburg, Germany). The nitrocellulose sheets 
were exposed to Kodak X-Omat AR films for 3 days. The 
autoradiograms of the anti-pp60 c-src Western blots were 
scanned with a Zeiss densitometer. The relative content of 
radioactivity determined for the pp60 csrc bands was esti- 
mated from the area underneath e peaks (sum of extinc- 
tions) and used for estimation of the relative amount of the 
protein in various fractions. 
2.4. Platelet aggregation 
Platelets were prepared as described above and used in 
450 /xl aliquots for each data point. The samples were 
stirred at approximately 1000 rpm at 37°C in an ICARE 
aggregometer (Marseille, France). Agonists were added in 
50/zl to a final concentration f 1 U/ml  for thrombin and 
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20 /xM for ADP. Results were recorded by a Kipp and 
Zonen BD9 plotter. 
3. Results 
Stirred suspensions of human platelets were stimulated 
for 60 s with thrombin, collagen, vasopressin, PMA, ADP, 
PGE 1, and sodium nitroprusside. Thrombin, collagen and 
vasopressin stimulate platelets via cell surface receptors, 
and downstream events then activate PKC [1,25], whereas 
PMA directly stimulates PKC. ADP induces a biphasic 
platelet aggregation response, and we observed that the 
second phase is reached within 60 s after stimulation with 
20 /zM ADP (data not shown). After stimulation the 
Triton-insoluble cytoskeletal fraction and the Triton-solu- 
ble fraction were prepared and immunoblotted with an 
anti-phosphotyrosine antibody that allows the detection of 
net increases in tyrosine phosphorylation. Agonists that 
activate platelets led to siimilar patterns of phospho- 
tyrosine-containing proteins in the cytoskeleton (Fig. 1). 
PGE1, which elevates the ceUular concentration of cyclic 
AMP (see Ref. [25]), did not increase tyrosine phospho- 
rylation as has already been confirmed for whole platelet 
lysates [9]. Sodium nitroprusside, which raises the concen- 
tration of cyclic GMP, also had no effect on the phospho- 
rylation pattern compared to resting platelets (data not 
shown). 
Time-dependent protein tyrosine phosphorylation caused 
by thrombin (1 U/ml)  and vasopressin (1.5/zM) is shown 
in detail in Fig. 2. Within 5 s of thrombin stimulation and 
20 s of vasopressin stimulation a drastic increase in the 
tyrosine content of two proteins (apparent molecular masses 
of 60 and 54 kDa) was found in the cytoskeletal fraction 
which further increased within 30 s (Fig. 2, panels A and 
C). The other tyrosine phosphorylated proteins had appar- 
ent molecular masses of 145, 130, 100, 85, 80, 56 and 38 
kDa. The corresponding Triton-soluble supernatant frac- 
tions contained tyrosine-phosphorylated proteins of 130, 
88, 70 and 60 kDa (Fig. 2, panel B), with the increase in 
tyrosine phosphorylation of the 88 kDa protein of un- 
known identity being most obvious (Fig, 2, panel B). The 
apparent molecular masses of the main protein bands were 
almost identical for thrombin and vasopressin stimulation 
(Fig, 2, panels A and C). 
The most prominent 60 kDa band in both supernatant 
and cytoskeletal fractions was found to comigrate xactly 
with pp60 c-src as examined by an anti-pp60 src immunoblot 
(data not shown). The phosphotyrosine-containing proteins 
of 56 and 54 kDa in the cytoskeletal fractions were not 
found in the Triton-soluble supernatant and they do not 
cross-react with anti-pp60 ~r`  antibodies used to probe the 
cytoskeletal fractions (see below, Fig. 4). Therefore, they 
are not likely to be degradation products of pp60 ¢-src 
because the anti-pp60 sr~ antibody (mAb 327) recognizes 
an epitope at the beginning of the SH3-domain of the 
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Fig. 2. Time course of the effect of thrombin and vasopressin o
phosphotyrosine content of platelet fractions. Washed platelets were 
treated with thrombin (1 U/ml) and [ArgS]vasopressin (1.5 /~M). Cyto- 
skeletal fractions and Triton-soluble fractions were prepared and immuno- 
blotted with anti-phosphotyrosine antibodies a  described in Section 2. 
(A) Time course of the increase in tyrosine phosphorylation n the 
cytoskeletal (Triton-insoluble) fractions during thrombin stimulation. (B) 
Triton-soluble fractions ( upematants) of the corresponding time course 
of panel A. The first and last lanes represent unstimulated controls. (C) 
Time course of tyrosine phosphorylation during stimulation with 
[ArgS]vasopressin in the cytoskeleton. The lanes of panels A and C 
represent 8.5 and 6.8.10 6 platelets per lane, respectively. The lanes of 
panel B represent 1.6.10 6 platelets due to the higher protein contents of
the supernatants. 
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molecule (amino acid residues 88-137)[26] and pp60 csrc 
is typically proteolyzed at a position closer to the N- 
terminus. Tyrosine-phosphorylated proteins of 60, 57 and 
55 kDa have also been observed in the Triton-insoluble 
fraction of human platelets timulated with U 46619, a 
prostaglandin H2 analogue [18]. 
We determined the thrombin concentration dependence 
for the tyrosine phosphorylation response and found a 
marked increase of protein tyrosine phosphorylation in the 
cytoskeleton with concentrations of thrombin higher than 
0.01 U/ml  (Fig. 3). At 0.01 U/ml, thrombin produced a
somewhat weaker response. Unidentified tyrosine- 
phosphorylated proteins of 130 kDa and 80 kDa were 
more elevated in the preparation using thrombin concentra- 
tions as low as 0.01 to 0.1 U/ml, supporting an earlier 
observation of Ferrell and Martin [9] that tyrosine 
phosphorylation f individual proteins occurs in different 
waves. The 130 kDa protein is one of the earliest phospho- 
rylated substrates of PTKs in the cytoskeleton of intact 
platelets. 
A protein with an apparent molecular mass of 38 kDa 
has been described previously as being selectively 
phosphorylated as a consequence of [ArgS]vasopressin 
stimulation of human platelets [27]. We observed, how- 
ever, a phosphotyrosine-containing protein of approxi- 
mately 38 kDa also after stimulation with thrombin and 
collagen. It is not clear if this 38 kDa protein is identical to 
the 38 kDa protein as described for vasopressin-stimulated 
platelets. 
Following agonist stimulation, the platelet cytoskeleton 
undergoes rapid reorganization, accumulating 90% of the 
total cellular myosin and 90% of actin ([28]; for a review 
see Ref. [29]). We were curious, therefore, whether the 
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Fig. 4. Translocation of pp60 ~-~'~ to the cytoskeletal fraction of thrombin- 
stimulated platelets. Platelets were treated for 180 s with thrombin (1 
U/ml), and cytoskeletal nd Triton-soluble fractions were isolated and 
immunoblotted with an apti-pp60 s'c mouse antibody as described in 
Section 2. The second anti-mouse IgG antibody was 1251-labelled and the 
resulting autoradiogram is shown. Lanes 1-4 contain 5 /xg of protein, 
and lanes 5 and 6 each represent cytoskeletal proteins from 6.106 
platelets of the corresponding preparations. Lanes: 1, 2, 5, 6: Triton-in- 
soluble fractions; 3, 4: Triton-soluble fractions; 1, 3, 5: thrombin-stimu- 
lated platelets, 2, 4, 6: unstimulated platelets. 
cytoskeleton becomes relatively enriched in pp60 c*'~ fol- 
lowing platelet activation, or whether the apparent translo- 
cation occurs concomitantly with the condensation f other 
proteins like myosin and actin. The distribution of pp60 ~sr~ 
in the Triton-soluble and insoluble fractions of resting and 
thrombin-stimulated platelets is shown in Fig. 4. The 
protein content of the cytoskeleton of activated platelets 
rises 2- to 4-fold compared to the controls (data not 
shown), which is slightly greater than the values Horvath 
et al. [17] reported. Densitometric s anning of the pp60 ~ .... 
bands of the autoradiograms (see Fig. 4) revealed that the 
pp60 csrc content in the cytoskeleton of stimulated platelets 
rises at least 5-fold compared to the controls. These results 
support he recent findings that pp60 ~'sr~ becomes enriched 
in the cytoskeleton of activated platelets [17-19]; the 
amount has been described as 40-55% of the total pp60 ~src 
in platelets [17,19]. 
4. Discussion 
0 .01 .05  .1 .2 .5 1 
thrombin concentration [U/ml] 
Fig. 3. Concentration-dependence of thrombin stimulation of the 
phosphotyrosine content of cytoskleletal proteins. Washed platelets were 
treated for 60 s with various concentrations of thrombin as indicated. 
Cytoskeletal fractions were prepared and immunoblotted with anti-phos- 
photyrosine antibody as described in Section 2. Each lane represents 
material from 7.5-106 platelets. 
The rapid increase in protein tyrosine phosphorylation 
in the cytoskeletal fraction within 5 s of thrombin addition 
we report here agrees well with our recent finding that 
pp60 ¢src becomes rapidly activated within 10 s and re- 
mains activated for at least 10 min following thrombin 
stimulation [13]. It is not clear why others found a transient 
pp60 c-src activation upon thrombin stimulation of normal 
platelets [12], but it can be due to differences in platelet 
preparation. We used a buffer of pH 6.4 in our protocol 
that minimizes pre-activation of the platelets during the 
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isolation procedure and allows them afterwards at pH 7.4 
to be able to be fully activated uring stimulation. 
In contrast to data provided by Clark and Brugge [12], 
we detected no prominent 12',0 kDa band that appeared to 
contain multiple tyrosine-phosphorylated proteins. Vin- 
culin, a 130 kDa protein, h~ts been recently described to 
undergo calcium-dependent tyrosine phosphorylation [30], 
but this phosphorylation was only detectable in the Triton- 
soluble fraction and may be one of the proteins of the 120 
kDa band mentioned above [12]. Although it was reported 
that the cytoskeletal fraction of thrombin-activated platelets 
became substantially enriched in vinculin in comparison to 
that of resting platelets [31], the amount of cytoskeletal- 
associated vinculin seems to be relatively small (10% or 
less of total) and may not be detectable as a phosphopro- 
tein by an anti-phosphotyrosine a tibody [30]. Therefore, 
the tyrosine-phosphorylated 130 kDa protein we detected 
in the Triton-soluble fraction is likely to be vinculin (Fig. 
2, panel B), but whether or not the 130 kDa protein in the 
cytoskeletal fraction is vinculin is less certain and remains 
to be investigated. 
In transformed cells two cytoskeleton-associated pro-
teins of 80 and 85 kDa (p80/85) have previously reported 
to be substrates for pp60 v~rc and activated mutants of 
pp60 ..... in which tyrosine-527 has been replaced by 
phenylalanine [32]. The 80,/85 kDa proteins have now 
been identified as F-actin-binding proteins enriched in the 
cell cortex, termed cortactin [33]. In thrombin-stimulated 
platelets p80/85 became rapidly tyrosine-phosphorylated 
(within 1 min of platelet activation) and transiently associ- 
ated with pp60 ¢~¢ [11]. Therefore, the tyrosine- 
phorphorylated proteins we t0und in the cytoskeletal frac- 
tion on agonist stimulation of platelets might be identical 
with cortactin, not only because of their cytoskeletal sso- 
ciation but also because tyrosine phosphorylation of 
p80/85 occurred very rapidly (within 15 s) and was 
completed within 1 min of stimulation (Figs. 1, 2A and C, 
3). Although the regulatory p85 subunit of phosphatidyl- 
inositol 3-kinase associates with the cytoskeleton and with 
the src-family tyrosine kinases p60 frn and pp60 c .... upon 
thrombin stimulation, it does not appear to become tyro- 
sine-phosphorylated [34]. 
A possible candidate for the weakly phosphorylated 70
kDa protein in the Triton-soluble fraction could be a 
cytosolic PTK, CPTK 71, previously described in bovine 
platelets [35] which might be', identical with p72 syk [15]. 
There appear to be a number of discrepancies among 
various reports concerning P.¢rosine-containing proteins in 
stimulated human platelets (e.g., see Refs. [6,9,12,13,18- 
20]). This might be due to different isolation procedures or 
different antibodies used, but also SDS-polyacrylamide g l 
analysis and the use of different protein molecular mass 
markers may produce variations. Whether differences in 
protein tyrosine phosphorylation observed with various 
biologically active agents (e.g. U 46619 vs. thrombin) 
represent different intracellular esponses and not just 
methodological differences remains to be verified. Isola- 
tion and identification of individual proteins hould solve 
this problem. 
Proteins phosphorylated on tyrosine residues appear 
very rapidly in the cytoskeletal fraction following platelet 
activation (Fig. 2, panels A and C), and the 60 kDa 
phosphotyrosine protein in the corresponding Triton-solu- 
ble fractions, likely tO be pp60 csrc, concomitantly disap- 
pears (Fig. 2, panel B). Therefore, we speculate that 
tyrosine phosphorylation f some proteins occurs in situ at 
the cytoskeleton. This is supported by the finding that 
proteins in the cytoskeleton fraction of thrombin-stimu- 
lated platelets can be phosphorylated in vitro by a cyto- 
skeletal-associated PTK activity [19], most likely pp60 ..... .
On the other hand, some proteins might become tyrosine- 
phosphorylated and then translocated to the cytoskeleton; 
to date, we have no evidence to distinguish between these 
possibilities. The protein tyrosine kinase pp60 csrc is be- 
lieved to play a role in late or postaggregational events in 
platelets [19]. But the rapid onset of protein tyrosine 
phosphorylation we found in the cytoskeleton following 
platelet activation and the extensive translocation f the 60 
kDa protein, most likely pp60 csr~, within 30 s of thrombin 
stimulation (Fig. 2, panels A and B) may signify a role for 
this protein in earlier events of platelet signalling. Re- 
cently, we described that agents that directly or indirectly 
activate PKC in intact platelets lead to rapid Ser-12 phos- 
phorylation of pp60 ¢sr~, which might be a necessary signal 
for translocation of pp60 ¢~r¢ from its anchorage in the 
plasma membrane to the cytoskeleton [13]; this is a further 
hint that translocation of pp60 ¢~r¢ (or of other activated 
PTKs in platelets) and protein tyrosine phosphorylation 
might be early, crucial events in platelet activation. We 
detected phosphorylation f a greater number of phospho- 
tyrosine-containing proteins in the cytoskeletal fraction 
than do others, even after 5 min of thrombin stimulation 
[19] and under similar stimulation conditions. Their use of 
a different detection system, a different platelet preparation 
protocol, and a phosphoimager for their documentation 
might be reasons for differing results. 
There is good evidence that the glycoprotein complex 
lib-Ilia (Gp lib-Ilia), by itself an in vitro substrate of 
pp60 csrc [36], is functionally coupled to both protein tyro- 
sine phosphorylation and cytoskeletal association of 
pp60 ~~r~ in activated platelets [18-20,37]; Gp IIb-IIIa also 
translocates to the cytoskeleton [18,19,31]. Phosphatidyl- 
inositol 3-kinase and phospholipase Cy l  are also associ- 
ated with the cytoskeleton [16,29]. The regulatory subunit 
of phosphatidylinositol 3-kinase (p85) and phospholipase 
Cy l  was present [38] in anti-phosphotyrosine mmuno- 
precipitates from extracts of thrombin-stimulated platelets, 
but only the latter has been found to be phosphorylated at 
tyrosine residues [39]. Both proteins contain SH2-domains, 
shown to be important determinants of protein-protein 
interaction, mainly with the cytoskeleton (reviewed in Ref. 
[40]). Most probably, more and other protein tyrosine 
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kinase substrates containing SH2 domains might be in- 
volved in platelet activation, including cytoskeletal compo- 
nents [16,31,32,41] and possibly G-proteins [42,43]. Identi- 
fication of more proteins phosphorylated on tyrosine 
residues hould give further insight into signal transduction 
mechanisms in human platelets. 
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